Caristo Diagnostics

Caristo Diagnostics is a cardiac imaging AI software company that develops proprietary technology to detect coronary inflammation and assess cardiovascular disease risk from coronary CT angiography (CCTA) imaging. The company's flagship platform, CaRi-Heart® Technology, combines AI-driven analysis with clinical cardiology to enable early detection of hidden inflammation associated with heart attack risk. Key product offerings include FAI-Score™ (Functional Assessment of Inflammation score for detecting coronary inflammation), CaRi-Plaque™ Analysis (quantifying and characterizing coronary plaque burden), and Individualised Risk Score (predicting cardiac events). Caristo serves multiple clinical applications: preventive screening for asymptomatic patients, disease diagnosis and risk stratification, drug clinical trials (as an imaging core lab), and intervention planning. The company has FDA 510(k) clearance, CPT code recognition from the American Medical Association, and demonstrated clinical utility through publications in The Lancet and presentations at major cardiology conferences (AHA, SCCT). Caristo operates imaging analysis centers globally and partners with leading pharmaceutical companies for atherosclerotic cardiovascular disease (ASCVD) trials. The company is positioned as a digital health innovator focused on transforming preventive cardiology through quantitative imaging biomarkers of coronary inflammation.